摘要
肺癌是发病率及死亡率最高的恶性肿瘤之一。而在大多数的非小细胞肺癌(NSCLC)中,肿瘤细胞都会表达出表皮生长因子受体(EGFR),这使得针对这些患者进行更加精确和靶向性的治疗具备了可能。EGFR异常调节的相关机制与靶向治疗的疗效及耐药性息息相关。本文将对NSCLC中EGFR的表达机制以及表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)在治疗NSCLC后出现的获得性耐药进行综述。
Lung cancer is one of the malignant tumors with the highest morbidity and mortality.Epidermal growth factor receptor is expressed in the majority of non-small cell lung cancer tumor cells,making it possible to give these patients more precise and targeted therapies.The mechanisms of abnormal EGFR regulation are closely related to the efficacy of targeted therapy and the occurrence of drug resistance.Therefore,this review will review the expression mechanism of EGFR in NSCLC and the acquired drug resistance of epidermal growth factor receptor tyrosine kinase inhibitor after treatment of NSCLC.
作者
邓斯元
朱旭
肖家荣
Deng Siyuan;Zhu Xu;Xiao Jiarong(Guizhou Medical University,Guiyang 550001,China;Department of Thoracic Surgery,the Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China)
出处
《中华内分泌外科杂志》
CAS
2023年第3期370-372,共3页
Chinese Journal of Endocrine Surgery
基金
贵州省科技计划项目(黔科合LH字[2017]7203号)。
关键词
非小细胞肺癌
表皮生长因子受体
酪氨酸激酶抑制剂
耐药性
Non-small cell lung cancer
Epidermal growth factor receptor
Tyrosine kinase inhibitor
Drug resistance
